Billionaires John Paulson and D.E. Shaw Like This Stock

PAULSON & COAccording to 13F filings for the second quarter, D.E. Shaw increased its position in Mylan Inc (NASDAQ:MYL) by 19% between the beginning of April and the end of June to 16.9 million shares. Mylan, which develops and manufactures both generic and branded pharmaceutical products and ingredients, is also a favorite of billionaire John Paulson’s Paulson & Co. Paulson left its position in the company unchanged during the second quarter at 24.5 million shares. Paulson and D.E. Shaw have often increased and decreased their stakes in Mylan over the past several quarters, but at the end of June it was the fifth largest position in Paulson’s portfolio according to the fund’s 13F (see more stock picks from John Paulson and D.E. Shaw). So far this year Mylan is up 7%, underperforming the NASDAQ index, but it has risen an impressive 11% since the end of June.

The most common investment thesis behind Mylan is that as an increasing number of drugs go off-patent in the coming years, Mylan will be able to develop and sell generic equivalents. The vast majority of Mylan’s revenue is generated by generic drugs, though higher sales of its branded auto-injector for treating allergic reactions caused high growth in the branded segment. Overall, revenues increased 7% in the second quarter compared to the same period a year ago; earnings slightly decreased, but thanks to a fall in share count earnings per share were essentially unchanged. In the first half of 2012, Mylan saw a 7% increase in earnings, as revenue grew 9%, as well as the fall in share count. This drove its earnings per share up to 62 cents, compared to 56 cents in the first half of 2011.

Mylan’s second quarter report beat the Street’s earnings expectations, something the company had done in the previous three quarters as well. The beats have been narrow, but should give investors more confidence in the company’s ability to meet sell-side targets in the future. At the moment, analyst consensus is for earnings per share of $2.74 for 2013 and, with half the year in the books, $2.51 for 2012; this implies a 9% EPS growth rate next year, about in line with what it has done so far this year. The trend in patent expiration gives the company avenues to future growth, and Mylan has recently announced a partnership with Pfizer Inc (NYSE:PFE) to produce generic drugs for the Japanese market. The sell-side’s expectations imply a forward P/E of 9, which seems cheap, and going out further the five-year PEG ratio is 0.9.

The two closest peers for Mylan are Teva Pharmaceutical Industries Ltd (NYSE:TEVA) and Watson Pharmaceuticals Inc (NYSE:WPI). Both companies, similarly to Mylan, produce both generic and branded drugs. Teva is a monster value stock on a quantitative basis: it trades at 11 times trailing earnings, 7 times forward earnings estimates, and is coming off a 50% bump in earnings compared to the same period in the previous year. At a $35 billion market capitalization, it is also over three times Mylan’s size. Over the longer term, however, the sell-side has its growth coming in just under the smaller company’s and its five-year PEG ratio is 1. We still think it might be better to take the value and a 2.1% dividend yield now rather than trust the Street. Watson has high growth targets, with its earnings per share expected to increase 40% in 2013 compared to 2012; the forward P/E is 10, but this is higher than either of its peers we’ve discussed and depends on what looks to be quite a bit of optimism. Considering future growth prospects all three of these companies seem like good investments in the trend of generic pharmaceuticals. Mylan is certainly a good pick if investors believe that D.E. Shaw ‘s and Paulson’s positions outweigh the narrowly better value in quantitative terms at Teva.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

Most Famous Gay Athletes

The World’s Most Famous Circuses

Best Hair Stylists

Most Popular NASCAR Drivers

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!